Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

S.W. Lam; S.M. de Groot; A.H. Honkoop; A. Jager; A.J. ten Tije; M.M.E.M. Bos; S.C. Linn; J. Bosch; J.R. Kroep; J.J. Braun; H. van Tinteren; E. Boven

doi:https://doi.org/10.1016/j.ejca.2014.10.008

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

S.W. Lam, S.M. de Groot, A.H. Honkoop, A. Jager, A.J. ten Tije, M.M.E.M. Bos, S.C. Linn, J. Bosch, J.R. Kroep, J.J. Braun, H. van Tinteren, E. Boven

Medical oncology (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

29 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	3077-3088
Journal	European Journal of Cancer
Volume	50
Issue number	18
DOIs	https://doi.org/10.1016/j.ejca.2014.10.008
Publication status	Published - 2014

Access to Document

https://doi.org/10.1016/j.ejca.2014.10.008

Cite this

Lam, S. W., de Groot, S. M., Honkoop, A. H., Jager, A., ten Tije, A. J., Bos, M. M. E. M., Linn, S. C., Bosch, J., Kroep, J. R., Braun, J. J., van Tinteren, H., & Boven, E. (2014). Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial. European Journal of Cancer, 50(18), 3077-3088. https://doi.org/10.1016/j.ejca.2014.10.008

@article{f1cb13f018a343a7911d49ec841b6bae,

title = "Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial",

author = "S.W. Lam and {de Groot}, S.M. and A.H. Honkoop and A. Jager and {ten Tije}, A.J. and M.M.E.M. Bos and S.C. Linn and J. Bosch and J.R. Kroep and J.J. Braun and {van Tinteren}, H. and E. Boven",

year = "2014",

doi = "https://doi.org/10.1016/j.ejca.2014.10.008",

language = "Undefined/Unknown",

volume = "50",

pages = "3077--3088",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "18",

}

Lam, SW, de Groot, SM, Honkoop, AH, Jager, A, ten Tije, AJ, Bos, MMEM, Linn, SC, Bosch, J, Kroep, JR, Braun, JJ, van Tinteren, H & Boven, E 2014, 'Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial', European Journal of Cancer, vol. 50, no. 18, pp. 3077-3088. https://doi.org/10.1016/j.ejca.2014.10.008

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial. / Lam, S.W.; de Groot, S.M.; Honkoop, A.H. et al.
In: European Journal of Cancer, Vol. 50, No. 18, 2014, p. 3077-3088.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

AU - Lam, S.W.

AU - de Groot, S.M.

AU - Honkoop, A.H.

AU - Jager, A.

AU - ten Tije, A.J.

AU - Bos, M.M.E.M.

AU - Linn, S.C.

AU - Bosch, J.

AU - Kroep, J.R.

AU - Braun, J.J.

AU - van Tinteren, H.

AU - Boven, E.

PY - 2014

Y1 - 2014

U2 - https://doi.org/10.1016/j.ejca.2014.10.008

DO - https://doi.org/10.1016/j.ejca.2014.10.008

M3 - Article

SN - 0959-8049

VL - 50

SP - 3077

EP - 3088

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 18

ER -